(MENAFN- GlobeNewsWire - Nasdaq) The market for VZV infection treatment is driven by increased vaccination and antiviral use, rising elderly populations, and strong immunization programs in developed regions. Key opportunities include expanding vaccine access in developing countries, R&D in new vaccine technologies, and managing competition from generics.

Dublin, Oct. 15, 2025 (GLOBE NEWSWIRE) -- The "Varicella Zoster Virus Infection Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 To 2033" report has been added to ResearchAndMarkets's offering.
The global varicella zoster virus (VZV) infection treatment market is projected to expand at a CAGR of 4.6% from 2025 to 2033, driven by rising vaccination programs, increasing awareness of viral infections, and growing elderly populations vulnerable to shingles.

This study report represents an analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

VZV, the causative agent of varicella (chickenpox) and herpes zoster (shingles), continues to present significant public health challenges, particularly in developing countries with limited vaccine penetration. Growing investments in antiviral therapies and immunization campaigns are shaping the market outlook.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Increasing Vaccination Coverage and Antiviral Use Driving Growth
The adoption of varicella and zoster vaccines is expanding globally, driven by government immunization programs and the rising demand for preventive healthcare. Advanced antiviral medications are also playing a crucial role in managing VZV infections, reducing symptom severity, and preventing complications such as post-herpetic neuralgia. Rising geriatric populations in North America, Europe, and Asia Pacific are fueling demand for shingles vaccines, with ongoing clinical research focusing on improving vaccine efficacy and extending immunity duration.
Limited Access and Safety Concerns as Challenges
Despite positive growth prospects, challenges persist due to limited vaccine access in low-income countries, high costs of advanced treatments, and safety concerns regarding immunocompromised patients. Vaccination hesitancy in certain regions further restricts coverage. Additionally, patent expirations of branded antivirals and vaccines may increase competition from generics, pressuring pricing strategies. However, increasing R&D in novel vaccine technologies, such as recombinant subunit and mRNA vaccines, is expected to provide long-term opportunities.
Market Segmentation by Indication
The market is segmented into varicella (chickenpox), herpes zoster (shingles), and other indications. In 2024, herpes zoster (shingles) accounted for the largest share, driven by rising cases among the aging population. Varicella remained significant in pediatric populations, particularly in countries where vaccination programs are still expanding. The others category includes complications such as post-herpetic neuralgia and ophthalmic zoster, which are gaining attention due to their impact on quality of life.
Market Segmentation by Age Group
By age group, the market is divided into paediatrics, adults, and geriatrics. In 2024, geriatrics held the largest share, driven by higher susceptibility to shingles and vaccine recommendations for elderly populations. Paediatrics remained a major segment due to ongoing chickenpox vaccination programs. Adults accounted for steady demand, especially in cases requiring shingles vaccination in middle-aged populations.
Regional Insights
In 2024, North America dominated the VZV treatment market, with strong vaccination programs in the U.S. and Canada, alongside high healthcare spending. Europe followed, with increasing adoption of shingles vaccines in countries such as Germany, France, and the UK. Asia Pacific is emerging as the fastest-growing market, with China, India, and Japan expanding immunization programs and pharmaceutical investments. Latin America and Middle East & Africa remain underpenetrated but represent growth potential with government-backed healthcare initiatives.
Competitive Landscape
The 2024 market featured both multinational pharmaceutical giants and regional biotech players. Merck & Co., GlaxoSmithKline, Pfizer, and Novartis led the global market with strong vaccine and antiviral portfolios. Sinovac, SK Chemicals, and Changchun BCHT Biotechnology played critical roles in regional vaccine production, particularly in Asia. Bausch Health, Glenmark Pharmaceuticals, Teva Pharmaceuticals, and Apotex supported antiviral drug offerings and generics. Sandoz, Kamada, and Mylan contributed to affordable treatment options across emerging markets. Bio-Rad Laboratories and Santa Cruz Biotechnology provided diagnostic and research solutions supporting clinical management and drug discovery. Competitive strategies are shaped by vaccine innovation, affordability, and global immunization partnerships.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Varicella Zoster Virus Infection Treatment market?
• What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2033.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Varicella Zoster Virus Infection Treatment market?
• Which is the largest regional market for Varicella Zoster Virus Infection Treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Varicella Zoster Virus Infection Treatment market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Varicella Zoster Virus Infection Treatment market worldwide?

Companies Featured

• Apotex
• Bausch Health
• Bio-Rad Laboratories
• Changchun BCHT Biotechnology
• GlaxoSmithKline
• Glenmark Pharmaceuticals
• Kamada
• Merck & Co.
• Mylan
• Novartis
• Pfizer
• Sandoz
• Santa Cruz Biotechnology
• Sinovac
• SK Chemicals

Market Segmentation

• Treatment Type
• Antiviral therapy
• Acyclovir
• Valacyclovir
• Famciclovir
• Other antiviral therapies
• Corticosteroids and anti-inflammatory agents
• Vaccines
• Other treatment types
• Indication
• Varicella (chicken pox)
• Herpes zoster (shingles)
• Other indications
• Age Group
• Paediatrics
• Adults
• Geriatrics
• Product Type
• Branded
• Generics
• Route of Administration
• Oral
• Topical
• Injectables
• End Use
• Hospitals and clinics
• Homecare settings
• Other end use

Region Segment (2023 - 2033; US$ Million)

• North America
• U.S.
• Canada
• Rest of North America
• UK and European Union
• UK
• Germany
• Spain
• Italy
• France
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East and Africa
• GCC
• Africa
• Rest of Middle East and Africa

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN15102025004107003653ID1110199666